1. Home
  2. AHCO vs ZYME Comparison

AHCO vs ZYME Comparison

Compare AHCO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdaptHealth Corp.

AHCO

AdaptHealth Corp.

HOLD

Current Price

$10.84

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$24.50

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHCO
ZYME
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
AHCO
ZYME
Price
$10.84
$24.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$13.50
$38.90
AVG Volume (30 Days)
1.4M
530.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$3,244,857,000.00
$105,965,000.00
Revenue This Year
$9.00
$183.10
Revenue Next Year
$6.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
38.87
52 Week Low
$8.33
$11.02
52 Week High
$13.43
$29.75

Technical Indicators

Market Signals
Indicator
AHCO
ZYME
Relative Strength Index (RSI) 33.66 39.64
Support Level $10.80 $22.28
Resistance Level $13.15 $27.54
Average True Range (ATR) 0.54 1.28
MACD -0.28 -0.52
Stochastic Oscillator 2.26 17.45

Price Performance

Historical Comparison
AHCO
ZYME

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: